Loss of the CBX7 Gene Expression Correlates with a Highly Malignant Phenotype in Thyroid Cancer
Authors:
Open Access
- 12 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (16) , 6770-6778
Abstract
Using gene expression profiling, we found that the CBX7 gene was drastically down-regulated in six thyroid carcinoma cell lines versus control cells. The aims of this study were to determine whether CBX7 is related to the thyroid cancer phenotype and to try to identify new tools for the diagnosis and prognosis of thyroid cancer. We thus evaluated CBX7 expression in various snap-frozen and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by quantitative reverse transcription-PCR and immunohistochemistry, respectively. CBX7 expression progressively decreased with malignancy grade and neoplasia stage. Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas. This finding coincides with results obtained in rat and mouse models of thyroid carcinogenesis. CBX7 loss of heterozygosity occurred in 36.8% of PTC and in 68.7% of ATC. Restoration of CBX7 expression in thyroid cancer cells reduced growth rate, with a retention in the G1 phase of the cell cycle, suggesting that CBX7 can contribute to the proliferation of the transformed thyroid cells. In conclusion, loss of CBX7 expression correlates with a highly malignant phenotype in thyroid cancer patients. [Cancer Res 2008;68(16):6770–8]Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence responseProceedings of the National Academy of Sciences, 2008
- Human Thyroid Tumor Cell Lines Derived from Different Tumor Types Present a Common Dedifferentiated PhenotypeCancer Research, 2007
- Role of the chromobox protein CBX7 in lymphomagenesisProceedings of the National Academy of Sciences, 2007
- The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progressionBritish Journal of Cancer, 2006
- Oncogenic rearrangements of the NTRK1/NGF receptorCancer Letters, 2006
- Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomasOncogene, 2005
- Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3Neuro-Oncology, 2005
- Chromosomal Imbalances in Post-Chernobyl Thyroid TumorsThyroid®, 2004
- The TRK-T1 fusion protein induces neoplastic transformation of thyroid epitheliumOncogene, 2000
- Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancerGenes, Chromosomes and Cancer, 1998